Yumanity Therapeutics Overview

  • Founded

  • 2014

Founded
  • Status

  • Public

  • Employees

  • 41

Employees
  • Stock Symbol

  • YMTX

Stock Symbol
  • Investments

  • 2

  • Share Price

  • $1.74

  • (As of Wednesday Closing)

Yumanity Therapeutics General Information

Description

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Contact Information

Website
www.yumanity.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 40 Guest Street
  • Suite 4410
  • Boston, MA 02135
  • United States
+1 (617) 000-0000

Yumanity Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Yumanity Therapeutics Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.74 $1.72 $0.95 - $13.90 $18.9M 10.8M 1.24M -$4.24

Yumanity Therapeutics Financials Summary

In Thousands,
USD 		TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 7,433 14,223 171,611
Revenue 5,534 8,044 6,896 0
EBITDA (41,750) (36,980) (54,789) (29,473)
Net Income (44,202) (39,503) (57,487) (31,209)
Total Assets 31,559 62,932 114,835 17,606
Total Debt 10,866 27,689 35,289 15,220
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Yumanity Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Yumanity Therapeutics‘s full profile, request access.

Request a free trial

Yumanity Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development
Drug Discovery
Boston, MA
41 As of 2021
00000
000000&0 00000

0000 0

s aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
0000000000000
Cambridge, MA
000 As of 0000
00.000
000000000 00.000

000000

ud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in re
0000 000000000
San Diego, CA
000 As of 0000
00000
0000000 0000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Yumanity Therapeutics Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SAGE Therapeutics Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
000000000 00000000 Private Equity-Backed San Diego, CA 000 00000 0000000 0000 00000
0000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
0000 Venture Capital-Backed San Diego, CA 00 00.000 0000000000 0
000000000000 Venture Capital-Backed Clarksville, MD 0 00.000 00000000000
You’re viewing 5 of 43 competitors. Get the full list »

Yumanity Therapeutics Patents

  • 30

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 6

    Pending

  • 000

    Expiring in next 12 mo

Yumanity Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020245349-A1 Compounds and uses thereof Pending 22-Mar-2019 0000000000
CA-3134510-A1 Compounds and uses thereof Pending 22-Mar-2019 0000000000
CA-3127791-A1 Compounds and uses thereof Pending 24-Jan-2019 0000000000
EP-3914593-A1 Compounds and uses thereof Pending 24-Jan-2019 0000000000
AU-2020212034-A1 Compounds and uses thereof Pending 24-Jan-2019 C07D413/14
To view Yumanity Therapeutics’s complete patent history, request access »

Yumanity Therapeutics Executive Team (13)

Name Title Board Seat Contact Info
Richard Peters Ph.D Chief Executive Officer & Board Member
Michael Wyzga Chief Financial Officer, Finance & Senior Vice President
Ellen Forest Chief Human Resources Officer
Daniel Tardiff Ph.D Scientific Co-founder & Vice President, Head of Translational Research
Paulash Mohsen Executive
You’re viewing 5 of 13 executive team members. Get the full list »

Yumanity Therapeutics Board Members (13)

Name Representing Role Since
Cecil Pickett Ph.D Yumanity Therapeutics Board Member 000 0000
David Arkowitz Self Board Member 000 0000
Jeffery Kelly Ph.D Self Board Member 000 0000
Kimberlee Drapkin Self Board Member 000 0000
Lynne Zydowsky Ph.D Yumanity Therapeutics Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Yumanity Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Yumanity Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Yumanity Therapeutics‘s full profile, request access.

Request a free trial

Yumanity Therapeutics Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 06-Jun-2022 0000000 00 Drug Discovery 0000000 0
Proteostasis Therapeutics 22-Dec-2020 Merger/Acquisition Drug Discovery 0000000 0
To view Yumanity Therapeutics’s complete acquisitions history, request access »